Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the US
Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the US
复制标题
DOI：
10.1177/003335490812300412
复制
发表时间：
2008-07-01
影响因子：
3.3
通讯作者：
Buffington, Joanna
中科院分区：
文献类型：
--
作者：
Miriti, M'Kiaira K.;Billah, Kaafee;Buffington, Joanna
目标。这项研究评估了一项在一年内为所有在性传播疾病(STD)诊所接受治疗的成年人接种疫苗的国家计划的长期经济影响。利用圣地亚哥(加利福尼亚州)、伊利诺伊州和丹佛(科罗拉多州)性病诊所已公布的来源和示范项目的数据，开发了一个模型，以跟踪一年内获得服务的200万名性病诊所客户的长期疾病结果和成本。该模型估计了在全国性病诊所常规接种乙肝疫苗政策与不接种疫苗的净经济效益。如果没有疫苗接种计划，估计在一年内看到的200万STD诊所客户的一生中，将发生237,021例新的乙肝病毒(乙肝)感染。与乙肝病毒相关的医疗成本和生产力损失将达到16亿美元。在一项在性病诊所常规接种疫苗的国家计划中，预计将有130万成年人至少接种一剂疫苗，预计在没有接种疫苗的情况下，预计将有45%的新乙肝病毒感染得到预防。疫苗接种计划将耗资1.38亿美元，尽管该计划仍会发生乙肝病毒感染，但将耗资8.78亿美元，客户的时间和旅行将耗资4500万美元。常规疫苗接种的净经济效益(节省)将为5.26亿美元。如果不考虑因感染乙肝而造成的生产力损失的间接成本，常规疫苗接种的净成本为2800万美元。这一模型的估计表明，在性病诊所为成年人进行常规乙肝疫苗接种的全国性计划将为社会节省成本。
Objective. This study assessed the long-term economic implications of a national program to vaccinate all adults treated at sexually transmitted disease (STD) clinics in a single year.Methods. A model was developed to track the long-term disease outcomes and costs among a hypothetical cohort of 2 million STD clinic clients accessing services in one year, using data from published sources and demonstration projects at STD clinics in San Diego (California), Illinois, and Denver (Colorado). The model estimated net economic benefits of a routine hepatitis B vaccination policy at STD clinics nationwide compared with no vaccination.Results. Without a vaccination program, an estimated 237,021 new hepatitis B virus (HBV) infections would occur over the lifetimes of the 2 million STD clinic clients seen in a single year. HBV-related medical costs and productivity losses would be $1.6 billion. In a national program for routine vaccination at STD clinics, 1.3 million adults would be expected to receive at least one vaccine dose, and an estimated 45% of the new HBV infections expected without vaccination would be prevented. The vaccination program would cost $138 million, HBV infections occurring despite the program would cost $878 million, and clients' time and travel would cost $45 million. The net economic benefit (savings) of routine vaccination would be $526 million. If the indirect costs of lost productivity due to HBV infection are not considered, routine vaccination would have a net cost of $28 million.Conclusions. Estimates from this model suggest a national program for routine hepatitis B vaccination of adults at STD clinics would be a cost saving to society.